Who is eligible for clinical trial NCT06989853?

Participants must meet protocol criteria for Methamphetamine Use Disorder. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06989853 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-05

Methamphetamine and Troriluzole (NCT06989853)

🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: William Stoops

🩺 Plain-English Summary (8th-Grade Level)

This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (14 items).

Location: Psychopharmacology of Addiction Laboratory — Lexington, Kentucky

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

able to speak/read English,
not seeking treatment for drug use at the time of the study,
female or male between the ages of 18 and 55 years,
recent methamphetamine use verified by methamphetamine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for MUD,
judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for MUD (and OUD for the co-morbid MUD and OUD group, see below) at the time of screening,
ECG, read by a cardiologist, within normal limits,
females using an effective form of birth control and not pregnant or breastfeeding,
no known contraindications (e.g., hepatic disease \[save for asymptomatic HCV status as cleared by study physician\]) or allergies to troriluzole. Individuals in the MUD and OUD group must also report recent opioid use, verified by opioid positive urine, as well as fulfillment of DSM-5 diagnostic criteria for OUD with physiologic dependence (determined to not be physically dependent if a participant arrives with a urine sample for drug screening that is negative for a short-acting opioid and does not have a score of 5 or greater on the clinical opioid withdrawal scale \[COWS\]).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
unable to speak/read English,
seeking treatment for drug use,
under 18 years or over 55 years,
no recent methamphetamine use as indicated by methamphetamine negative urine and no DSM-5 diagnosis of MUD,
judged to be medically and psychiatrically unhealthy by study physicians at the time of screening,
ECG, read by a cardiologist, outside normal limits,
females not using an effective form of birth control or pregnant or breastfeeding,
blood pressure readings indicative of hypertension (i.e., blood pressure \> 140/90 mmHg) on 2 consecutive screening visits,
BMI \< 18 or \> 30; weight \< 50 kg,
taking any medications prescribed by a physician for a chronic condition,
any laboratory chemistry values (e.g., LFTs) \> 3 times normal at screening or during admission,

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Psychopharmacology of Addiction Laboratory — Lexington, Kentucky

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗